Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

The γ-Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice

(2018) Claudia Balducci et al.   JOURNAL OF ALZHEIMERS DISEASE

Stimulating Nicotinic Receptors Trigger Multiple Pathways Attenuating Cytotoxicity in Models of Alzheimer's and Parkinson's Diseases

(2018) Jun Kawamata et al.   JOURNAL OF ALZHEIMERS DISEASE

Effects of AZD3480 on Cognition in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase IIb Dose-Finding Study

(2018) Lutz Frölich et al.   JOURNAL OF ALZHEIMERS DISEASE

Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?

(2017) Robert E. Becker et al.   JOURNAL OF ALZHEIMERS DISEASE

CHF5074, a Novel γ-Secretase Modulator, Restores Hippocampal Neurogenesis Potential and Reverses Contextual Memory Deficit in a Transgenic Mouse Model of Alzheimer's Disease

(2017) Bruno P. Imbimbo et al.   JOURNAL OF ALZHEIMERS DISEASE

Acute Effect on the Aβ Isoform Pattern in CSF in Response to γ-Secretase Modulator and Inhibitor Treatment in Dogs

(2017) Erik Portelius et al.   JOURNAL OF ALZHEIMERS DISEASE

PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

(2017) Noel G. Faux et al.   JOURNAL OF ALZHEIMERS DISEASE

Propargylamine Containing Compounds as Modulators of Proteolytic Cleavage of Amyloid Protein Precursor: Involvement of MAPK and PKC Activation

(2017) Orit Bar-Am et al.   JOURNAL OF ALZHEIMERS DISEASE

M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models

(2015) Moussa B.H. Youdim   PARKINSONISM & RELATED DISORDERS

Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency

(2012) Kambiz N. Alavian et al.   BRAIN RESEARCH

Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?

(2012) Daniele De Filippis et al.   CNS & Neurological Disorders-Drug Targets

EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study

(2012) B. Vellas et al.   Current Alzheimer Research

Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases

(2012) L. Pisani et al.   CURRENT MEDICINAL CHEMISTRY

Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents

(2012) Carles Galdeano et al.   CURRENT PHARMACEUTICAL DESIGN

Differential Effects between  -Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice

(2012) Y. Mitani et al.   JOURNAL OF NEUROSCIENCE

Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model

(2012) C. Sunyach et al.   NEUROPHARMACOLOGY

ACS Chemical Neuroscience Molecule Spotlight on ELND006: Another γ-Secretase Inhibitor Fails in the Clinic

(2011) Corey R. Hopkins   ACS Chemical Neuroscience

PPAR gamma/RXR induced and CD36-mediated Abeta phagocytosis results in cognitive improvement in APP/PS1 mice

(2011) Mitsugu Yamanaka et al.   Alzheimers & Dementia

Identification of Exebryl-1® and other novel small molecules as tau protein aggregation inhibitors

(2011) Qubai Hu et al.   Alzheimers & Dementia

The gamma-secretase inhibitor BMS-708163 causes dose-dependent reductions in CSF Aβ40 levels in patients with mild-to-moderate Alzheimer's disease (AD)

(2011) Charles Albright et al.   Alzheimers & Dementia

Relationship Between Late-Life Hypertension, Blood Pressure, and Alzheimer’s Disease

(2011) Yuan-Han Yang et al.   American Journal of Alzheimers Disease and Other Dementias

ST101 induces a novel 17kDa APP cleavage that precludes Aβ generation in vivo

(2011) Kim N. Green et al.   ANNALS OF NEUROLOGY

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

(2011) Paul S. Aisen et al.   Archives of Medical Science

T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice

(2011) Tetsuo Fukushima et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease

(2011) Tanya L. Wallace et al.   BIOCHEMICAL PHARMACOLOGY

Alzheimer's disease & metals: therapeutic opportunities

(2011) Vijaya B Kenche et al.   BRITISH JOURNAL OF PHARMACOLOGY

A Step Further Towards Multitarget Drugs for Alzheimer and Neuronal Vascular Diseases: Targeting the Cholinergic System, Amyloid-β Aggregation and Ca2++ Dyshomeostasis

(2011) R. Leon et al.   CURRENT MEDICINAL CHEMISTRY

Multi-Target-Directed Ligands in Alzheimer's Disease Treatment

(2011) M. Bajda et al.   CURRENT MEDICINAL CHEMISTRY

Interacting with γSecretase for Treating Alzheimer's Disease: From Inhibition to Modulation

(2011) F. Panza et al.   CURRENT MEDICINAL CHEMISTRY

NAP (Davunetide) Provides Functional and Structural Neuroprotection

(2011) Illana Gozes   CURRENT PHARMACEUTICAL DESIGN

Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease

(2011) Angela Rampa et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

The preclinical discovery of amyotrophic lateral sclerosis drugs

(2011) Marcie A Glicksman   Expert Opinion on Drug Discovery

Novel therapy in Parkinson's disease: adenosine A2Areceptor antagonists

(2011) Nikoletta Szabó et al.   Expert Opinion on Drug Metabolism & Toxicology

Emerging drugs for amyotrophic lateral sclerosis

(2011) Ali Aamer Habib et al.   EXPERT OPINION ON EMERGING DRUGS

Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?

(2011) Sebastiaan Kuhne et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Istradefylline for the treatment of Parkinson's disease

(2011) Ariane Park et al.   EXPERT OPINION ON PHARMACOTHERAPY

Novel γ-secretase modulators: a review of patents from 2008 to 2010

(2011) Martin Pettersson et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib

(2011) Juan Manuel Domínguez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen

(2011) Jack T. Rogers et al.   JOURNAL OF NEURAL TRANSMISSION

Developing β-secretase inhibitors for treatment of Alzheimer’s disease

(2011) Arun K. Ghosh et al.   JOURNAL OF NEUROCHEMISTRY

The Alzheimer’s therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity

(2011) Peter J. Crouch et al.   JOURNAL OF NEUROCHEMISTRY

Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP Signaling

(2011) Y.-F. Li et al.   JOURNAL OF NEUROSCIENCE

Selective Hippocampal Neurodegeneration in Transgenic Mice Expressing Small Amounts of Truncated A  Is Induced by Pyroglutamate-A  Formation

(2011) A. Alexandru et al.   JOURNAL OF NEUROSCIENCE

Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach

(2011) Nikoletta Szabó et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Unknown

(2011) Daniel Paris et al.   MOLECULAR MEDICINE

Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials

(2011) Cristina Sampaio et al.   MOVEMENT DISORDERS

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

(2011) Merit Cudkowicz et al.   NATURE MEDICINE

Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets

(2011) Mali Jiang et al.   NATURE MEDICINE

Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway

(2011) Hyunkyung Jeong et al.   NATURE MEDICINE

Priorities in Parkinson's disease research

(2011) Wassilios G. Meissner et al.   NATURE REVIEWS DRUG DISCOVERY

“Lest we forget you — methylene blue …”

(2011) R. Heiner Schirmer et al.   NEUROBIOLOGY OF AGING

Mice Lacking Major Brain Gangliosides Develop Parkinsonism

(2011) Gusheng Wu et al.   NEUROCHEMICAL RESEARCH

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis

(2011) L. M. Duffy et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment

(2011) Fei Shen et al.   NEUROPHARMACOLOGY

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

(2011) Jos Prickaerts et al.   NEUROPHARMACOLOGY

Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

(2011) Marie Therese Armentero et al.   PHARMACOLOGY & THERAPEUTICS

Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors

(2011) Haythum O. Tayeb et al.   PHARMACOLOGY & THERAPEUTICS

Sodium/myo-Inositol Transporters: Substrate Transport Requirements and Regional Brain Expression in the TgCRND8 Mouse Model of Amyloid Pathology

(2011) Daniela Fenili et al.   PLoS One

The emergence of designed multiple ligands for neurodegenerative disorders

(2011) Werner J. Geldenhuys et al.   PROGRESS IN NEUROBIOLOGY

The future of Alzheimer's disease: The next 10 years

(2011) Harald Hampel et al.   PROGRESS IN NEUROBIOLOGY

Treating brain tumors with PDE4 inhibitors

(2011) Rajarshi Sengupta et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Site-Activated Chelators Targeting Acetylcholinesterase and Monoamine Oxidase for Alzheimer’s Therapy

(2010) Hailin Zheng et al.   ACS Chemical Biology

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Nic5-15: a novel natural gamma-secretase inhibitor that attenuates brain beta-amyloid content and improves cognition

(2010) Giulio Pasinetti et al.   Alzheimers & Dementia

Evp-6124: Safety, Tolerability And Cognitive Effects Of A Novel A7 Nicotinic Receptor Agonist In Alzheimer'S Disease Patients On Stable Donepezil Or Rivastigmine Therapy

(2010) Dana Hilt et al.   Alzheimers & Dementia

APP-selective gamma secretase inhibitor ELND006 effects on brain parenchymal and vascular amyloid beta in the PDAPP mouse model of Alzheimer's disease

(2010) Sally Schroeter et al.   Alzheimers & Dementia

E2012, a novel gamma-secretase modulator, decreases plasma amyloid-beta (Aβ) levels in humans

(2010) Christa Nagy et al.   Alzheimers & Dementia

Real-time Microdialysis for aβ Inhibition And Pk/pd Analysis in A Nonhuman Primate Model: In Vivo Efficacy of a Bace-1 Inhibitor

(2010) Jeremy Yu et al.   Alzheimers & Dementia

Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities

(2010) Ines Batinic-Haberle et al.   AMINO ACIDS

The cholinergic system in aging and neuronal degeneration

(2010) Reinhard Schliebs et al.   BEHAVIOURAL BRAIN RESEARCH

Recent developments in adenosine receptor ligands and their potential as novel drugs

(2010) Christa E. Müller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment

(2010) Michel Gallant et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

SK-PC-B70M alleviates neurologic symptoms in G93A-SOD1 amyotrophic lateral sclerosis mice

(2010) Ji-Seon Seo et al.   BRAIN RESEARCH

Combined Therapy with Idebenone and Deferiprone in Patients with Friedreich’s Ataxia

(2010) Daniel Velasco-Sánchez et al.   CEREBELLUM

An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers

(2010) David J. Brooks et al.   CLINICAL NEUROPHARMACOLOGY

Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection

(2010) Zsigmond Tamas Kincses et al.   CNS Neuroscience & Therapeutics

Heparin/heparan sulphate-based drugs

(2010) Neha S. Gandhi et al.   DRUG DISCOVERY TODAY

Etazolate improves performance in a foraging and homing task in aged rats

(2010) Jason Drott et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pharma–nutrition interface: The gap is narrowing

(2010) Niki A. Georgiou et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

An in vivo pharmacological evaluation of pardoprunox (SLV308) — A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease

(2010) C.A. Jones et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Oral Administration of a GSK3 Inhibitor Increases Brain Insulin-like Growth Factor I Levels

(2010) Marta Bolós et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

γ-Secretase Modulators as Potential Disease Modifying Anti-Alzheimer’s Drugs

(2010) Daniel Oehlrich et al.   JOURNAL OF MEDICINAL CHEMISTRY

The γ-Secretase Modulator CHF5074 Reduces the Accumulation of Native Hyperphosphorylated Tau in a Transgenic Mouse Model of Alzheimer’s Disease

(2010) Annamaria Lanzillotta et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration

(2010) David T. Dexter et al.   JOURNAL OF NEURAL TRANSMISSION

Alpha-secretase in Alzheimer’s disease: molecular identity, regulation and therapeutic potential

(2010) Stefan F. Lichtenthaler   JOURNAL OF NEUROCHEMISTRY

The relevance of iron in the pathogenesis of Parkinson’s disease

(2010) Jeswinder Sian-Hülsmann et al.   JOURNAL OF NEUROCHEMISTRY

Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease

(2010) K. J. Black et al.   JOURNAL OF NEUROSCIENCE

Acute  -Secretase Inhibition of Nonhuman Primate CNS Shifts Amyloid Precursor Protein (APP) Metabolism from Amyloid-  Production to Alternative APP Fragments without Amyloid-  Rebound

(2010) J. J. Cook et al.   JOURNAL OF NEUROSCIENCE

Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer's Disease

(2010) J. D. Brioni et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

RG3487, a Novel Nicotinic  7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents

(2010) T. L. Wallace et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative

(2010) Vanessa Villard et al.   JOURNAL OF PSYCHOPHARMACOLOGY

GM1 ganglioside in Parkinson's disease: Results of a five year open study

(2010) Jay S. Schneider et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions

(2010) Sheila M. Fleming et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Bringing natural products into the fold – exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases

(2010) P. Matthew Joyner et al.   NATURAL PRODUCT REPORTS

Natural products as a source of Alzheimer's drug leads

(2010) Philip Williams et al.   NATURAL PRODUCT REPORTS

Alzheimer's disease: strategies for disease modification

(2010) Martin Citron   NATURE REVIEWS DRUG DISCOVERY

Dimebon Inhibits Calcium-Induced Swelling of Rat Brain Mitochondria But Does Not Alter Calcium Retention or Cytochrome C Release

(2010) Kranthi Kumari Naga et al.   NEUROMOLECULAR MEDICINE

HDAC inhibitors and neurodegeneration: At the edge between protection and damage

(2010) Karen C. Dietz et al.   PHARMACOLOGICAL RESEARCH

Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases

(2010) C. Gibrat et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25–35 or Aβ1–40 peptide in rats

(2010) Yu-Fang Cheng et al.   PSYCHOPHARMACOLOGY

The sigma-1 receptor chaperone as an inter-organelle signaling modulator

(2010) Tsung-Ping Su et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

(2010) Kevin W. Gillman et al.   ACS Medicinal Chemistry Letters

Exebryl-1: A novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer's disease

(2009) Alan D. Snow et al.   Alzheimers & Dementia

In vivo efficacy of BACE-1 inhibitor CTS21166 (ASP1702) in rat CNS compartments

(2009) Jeremy Yu et al.   Alzheimers & Dementia

R3487/MEM 3454, a novel nicotinic alpha 7 receptor partial agonist, improves attention and working memory performance in cynomolgus macaques

(2009) T.L. Wallace et al.   BIOCHEMICAL PHARMACOLOGY

TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

(2009) T.A. Hauser et al.   BIOCHEMICAL PHARMACOLOGY

Sirtuins inhibitors: The approach to affinity and selectivity

(2009) Yana Cen   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?

(2009) Wenjie Luo et al.   BMC NEUROSCIENCE

The Role of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) in Alzheimer’s Disease

(2009) Qingguang Jiang et al.   CNS DRUGS

Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges

(2009) Richard Morphy et al.   CURRENT PHARMACEUTICAL DESIGN

Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors

(2009) Albert Fournier et al.   Expert Review of Neurotherapeutics

Inhibitors for Human Glutaminyl Cyclase by Structure Based Design and Bioisosteric Replacement

(2009) Mirko Buchholz et al.   JOURNAL OF MEDICINAL CHEMISTRY

The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal

(2009) John Hardy   JOURNAL OF NEUROCHEMISTRY

Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein  -Secretase for the Treatment of Alzheimer's Disease

(2009) R. L. Martone et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

(2009) R. A. Hodgson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease

(2009) Velandai Srikanth et al.   NEUROBIOLOGY OF AGING

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model

(2009) Natalia Shiryaev et al.   NEUROBIOLOGY OF DISEASE

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease

(2009) A. H.V. Schapira   NEUROLOGY

Adenosine, adenosine A2A antagonists, and Parkinson's disease

(2009) P. Jenner et al.   PARKINSONISM & RELATED DISORDERS

The pharmacology of sigma-1 receptors

(2009) Tangui Maurice et al.   PHARMACOLOGY & THERAPEUTICS

Multiple roles of HDAC inhibition in neurodegenerative conditions

(2009) De-Maw Chuang et al.   TRENDS IN NEUROSCIENCES

Discovery and development of heat shock protein 90 inhibitors

(2008) Tony Taldone et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The histamine H3receptor: an attractive target for the treatment of cognitive disorders

(2008) T A Esbenshade et al.   BRITISH JOURNAL OF PHARMACOLOGY

KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the Treatment of Amyotrophic Lateral Sclerosis

(2008) Valentin K. Gribkoff et al.   CNS Neuroscience & Therapeutics

Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice

(2008) Hidefumi Ito et al.   EXPERIMENTAL NEUROLOGY

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson’s disease

(2008) Naomi P. Visanji et al.   FASEB JOURNAL

Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+

(2008) Yongfang Zhang et al.   FEBS LETTERS

The neuroprotective mechanism of action of the multimodal drug ladostigil

(2008) Orly Weinreb   Frontiers in Bioscience-Landmark

Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s disease

(2008) Judit Pallos et al.   HUMAN MOLECULAR GENETICS

Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

(2008) Andrea Cavalli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells

(2008) Francisco Molina-Holgado et al.   JOURNAL OF NEUROCHEMISTRY

Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS

(2008) Bernadett Kalmar et al.   JOURNAL OF NEUROCHEMISTRY

The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2

(2008) L. Wang et al.   JOURNAL OF NEUROSCIENCE

From Dual Binding Site Acetylcholinesterase Inhibitors to Multi-Target-Directed Ligands (MTDLs): A Step Forward in the Treatment of Alzheimers Disease

(2008) Maria Bolognesi et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

(2008) Merit E. Cudkowicz et al.   MUSCLE & NERVE

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

(2008) Stephan Schilling et al.   NATURE MEDICINE

Sirtuins — novel therapeutic targets to treat age-associated diseases

(2008) Siva Lavu et al.   NATURE REVIEWS DRUG DISCOVERY

Regulation of M1-receptor mRNA stability by smilagenin and its significance in improving memory of aged rats

(2008) Yaer Hu et al.   NEUROBIOLOGY OF AGING

A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice

(2008) Toshiyuki Kawasaki et al.   NEUROPHARMACOLOGY

Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression

(2008) J.C. Lauterborn et al.   NEUROSCIENCE

Neuroprotection for Huntington’s disease: Ready, set, slow

(2008) Steven M. Hersch et al.   Neurotherapeutics

Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer’s disease

(2008) Maria Laura Bolognesi et al.   Neurotherapeutics

Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease

(2008) Jacobus P. Petzer et al.   Neurotherapeutics

Restraining tumor necrosis factor-alpha by thalidomide prevents the Amyloid beta-induced impairment of recognition memory in mice

(2007) Tursun Alkam et al.   BEHAVIOURAL BRAIN RESEARCH

Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV

(2007) Lichuan Yang et al.   EXPERIMENTAL NEUROLOGY

Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-α in an animal model of inflamed Alzheimer’s disease brain

(2007) Jae K. Ryu et al.   NEUROBIOLOGY OF DISEASE